| scholarly article | Q13442814 |
| P2093 | author name string | Jutta Wanner | |
| Karine G. Le Roch | |||
| Marco A. Biamonte | |||
| P2860 | cites work | A new world malaria map: Plasmodium falciparum endemicity in 2010 | Q17485680 |
| Global malaria mortality between 1980 and 2010: a systematic analysis | Q20905423 | ||
| Dihydroartemisinin/Piperaquine: a review of its use in the treatment of uncomplicated Plasmodium falciparum malariaedit | Q21032449 | ||
| Artemisinin resistance: current status and scenarios for containment | Q21032505 | ||
| Artemisinin-resistant malaria: research challenges, opportunities, and public health implications | Q21032532 | ||
| Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration | Q21034080 | ||
| A review of malaria vaccine clinical projects based on the WHO rainbow table | Q21034112 | ||
| A Concise Synthesis of (+)-Artemisinin | Q22061915 | ||
| Continuous-Flow Synthesis of the Anti-Malaria Drug Artemisinin | Q22061979 | ||
| Artemether-lumefantrine (six-dose regimen) for treating uncomplicated falciparum malaria | Q24245437 | ||
| Thousands of chemical starting points for antimalarial lead identification | Q24289329 | ||
| Spiroindolones, a potent compound class for the treatment of malaria | Q24606915 | ||
| Drug screen targeted at Plasmodium liver stages identifies a potent multistage antimalarial drug | Q24613311 | ||
| Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial | Q24630683 | ||
| Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction | Q24678060 | ||
| Potent antimalarial 4-pyridones with improved physico-chemical properties | Q84718196 | ||
| New bis-thiazolium analogues as potential antimalarial agents: design, synthesis, and biological evaluation | Q85841356 | ||
| Prodrugs of bisthiazolium salts are orally potent antimalarials | Q37585368 | ||
| A pre-emptive strike against malaria's stealthy hepatic forms | Q37624398 | ||
| Targeting the hypnozoite reservoir of Plasmodium vivax: the hidden obstacle to malaria elimination | Q37687630 | ||
| Road towards new antimalarials - overview of the strategies and their chemical progress | Q37823625 | ||
| Therapeutic potential of boron-containing compounds | Q37855884 | ||
| Target identification and validation of novel antimalarials | Q37894700 | ||
| A toolbox to study liver stage malaria | Q37947849 | ||
| Back to the future: lessons learned in modern target-based and whole-cell lead optimization of antimalarials. | Q37975527 | ||
| Small molecule anti-malarial patents: a review (January 2010-June 2011). | Q38018392 | ||
| Recent results in protein kinase inhibition for tropical diseases | Q38051892 | ||
| Plasmodium cell biology should inform strategies used in the development of antimalarial transmission-blocking drugs | Q38066991 | ||
| G6PD deficiency: global distribution, genetic variants and primaquine therapy | Q38079323 | ||
| Ketotifen is an antimalarial prodrug of norketotifen with blood schizonticidal and liver-stage efficacy. | Q38465613 | ||
| A single, low, oral dose of a 5-carbon-linked trioxane dimer orthoester plus mefloquine cures malaria-infected mice | Q38480612 | ||
| Public health: Death at the doorstep | Q38868062 | ||
| Identification of a new chemical class of antimalarials | Q38924120 | ||
| Identification and In-Vitro ADME Assessment of a Series of Novel Anti-Malarial Agents Suitable for Hit-to-Lead Chemistry | Q38982327 | ||
| Benzoheterocyclic amodiaquine analogues with potent antiplasmodial activity: synthesis and pharmacological evaluation | Q39322349 | ||
| Antimalarial activity of pyrroloiminoquinones from the Australian marine sponge Zyzzya sp. | Q39333451 | ||
| Enhanced gametocyte production in Fansidar-treated Plasmodium falciparum malaria patients: implications for malaria transmission control programmes | Q39371852 | ||
| Design, synthesis, and in vitro activity of novel 2'-O-substituted 15-membered azalides | Q39387631 | ||
| Antimalarial activity of 9a-N substituted 15-membered azalides with improved in vitro and in vivo activity over azithromycin | Q39431851 | ||
| Synthesis, antimalarial activity, and structure-activity relationship of 7-(2-phenoxyethoxy)-4(1H)-quinolones | Q39438178 | ||
| Optimization of Potent Inhibitors of P. falciparum Dihydroorotate Dehydrogenase for the Treatment of Malaria | Q39469622 | ||
| Quinoline antimalarials containing a dibemethin group are active against chloroquinone-resistant Plasmodium falciparum and inhibit chloroquine transport via the P. falciparum chloroquine-resistance transporter (PfCRT). | Q39482802 | ||
| Extracting SAR Information from a Large Collection of Anti-Malarial Screening Hits by NSG-SPT Analysis | Q39513261 | ||
| Imidazolopiperazines: hit to lead optimization of new antimalarial agents. | Q39530026 | ||
| Antimalarial efficacy and drug interactions of the novel semi-synthetic endoperoxide artemisone in vitro and in vivo. | Q39563304 | ||
| Antimalarial histone deacetylase inhibitors containing cinnamate or NSAID components | Q39588840 | ||
| Synthesis and structure-activity relationships of novel benzoxaboroles as a new class of antimalarial agents | Q39613380 | ||
| Spirotetrahydro beta-carbolines (spiroindolones): a new class of potent and orally efficacious compounds for the treatment of malaria. | Q39616001 | ||
| Identification, design and biological evaluation of heterocyclic quinolones targeting Plasmodium falciparum type II NADH:quinone oxidoreductase (PfNDH2). | Q35958086 | ||
| Liver-stage malaria parasites vulnerable to diverse chemical scaffolds | Q36001246 | ||
| Transmission of malaria to mosquitoes blocked by bumped kinase inhibitors | Q36005409 | ||
| The spiroindolone drug candidate NITD609 potently inhibits gametocytogenesis and blocks Plasmodium falciparum transmission to anopheles mosquito vector | Q36086489 | ||
| Pharmacokinetics and pharmacodynamics of piperaquine in a murine malaria model | Q36422706 | ||
| A combined transcriptome and proteome survey of malaria parasite liver stages | Q36423509 | ||
| Perspective: artemisinin-resistant malaria and the wolf | Q36450587 | ||
| Counter perspective: artemisinin resistance: facts, fears, and fables | Q36450590 | ||
| 4(1H)-Quinolones with liver stage activity against Plasmodium berghei. | Q36505423 | ||
| First-in-man safety and pharmacokinetics of synthetic ozonide OZ439 demonstrates an improved exposure profile relative to other peroxide antimalarials | Q36573154 | ||
| In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen | Q36736936 | ||
| The threat of artemisinin-resistant malaria | Q37069786 | ||
| Evaluation of artemisone combinations in Aotus monkeys infected with Plasmodium falciparum | Q37274770 | ||
| Artemisinin-naphthoquine combination (ARCO) therapy for uncomplicated falciparum malaria in adults of Papua New Guinea: a preliminary report on safety and efficacy | Q37325659 | ||
| Understanding the pharmacokinetics of Coartem | Q37383289 | ||
| Primaquine in vivax malaria: an update and review on management issues | Q27003856 | ||
| Structure-Guided Lead Optimization of Triazolopyrimidine-Ring Substituents Identifies Potent Plasmodium falciparum Dihydroorotate Dehydrogenase Inhibitors with Clinical Candidate Potential | Q27670499 | ||
| Malarial dihydrofolate reductase as a paradigm for drug development against a resistance-compromised target | Q27674154 | ||
| Factors influencing the specificity of inhibitor binding to the human and malaria parasite dihydroorotate dehydrogenases | Q27679263 | ||
| Imaging of Plasmodium Liver Stages to Drive Next-Generation Antimalarial Drug Discovery | Q27861956 | ||
| Thiostrepton and derivatives exhibit antimalarial and gametocytocidal activity by dually targeting parasite proteasome and apicoplast | Q27973422 | ||
| Glutathione reductase-catalyzed cascade of redox reactions to bioactivate potent antimalarial 1,4-naphthoquinones--a new strategy to combat malarial parasites | Q28241079 | ||
| Targeting protein kinases in the malaria parasite: update of an antimalarial drug target | Q28257406 | ||
| Glucose-6-phosphate dehydrogenase deficiency | Q28263721 | ||
| Marine actinomycetes: a new source of compounds against the human malaria parasite | Q28472855 | ||
| Establishment of an in vitro assay for assessing the effects of drugs on the liver stages of Plasmodium vivax malaria | Q28476463 | ||
| The next opportunity in anti-malaria drug discovery: the liver stage | Q28477177 | ||
| Towards an in vitro model of Plasmodium hypnozoites suitable for drug discovery | Q28477602 | ||
| Integrated dataset of screening hits against multiple neglected disease pathogens | Q28478485 | ||
| The activities of current antimalarial drugs on the life cycle stages of Plasmodium: a comparative study with human and rodent parasites | Q28480979 | ||
| Activity of clinically relevant antimalarial drugs on Plasmodium falciparum mature gametocytes in an ATP bioluminescence "transmission blocking" assay | Q28482292 | ||
| Discovery of gene function by expression profiling of the malaria parasite life cycle | Q29547840 | ||
| Chemical genetics of Plasmodium falciparum | Q29617272 | ||
| Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase | Q33272939 | ||
| A systematic approach to understand the mechanism of action of the bisthiazolium compound T4 on the human malaria parasite, Plasmodium falciparum | Q33381401 | ||
| Structure-activity relationships amongst 4-position quinoline methanol antimalarials that inhibit the growth of drug sensitive and resistant strains of Plasmodium falciparum | Q33526131 | ||
| A repurposing strategy identifies novel synergistic inhibitors of Plasmodium falciparum heat shock protein 90. | Q33547134 | ||
| Discovery of Novel Benzo[a]phenoxazine SSJ-183 as a Drug Candidate for Malaria | Q33557946 | ||
| An Invitation to Open Innovation in Malaria Drug Discovery: 47 Quality Starting Points from the TCAMS | Q33598760 | ||
| A Divergent SAR Study Allows Optimization of a Potent 5-HT2c Inhibitor to a Promising Antimalarial Scaffold | Q33630572 | ||
| In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda | Q33676088 | ||
| Identification of inhibitors for putative malaria drug targets among novel antimalarial compounds | Q33682916 | ||
| A research agenda for malaria eradication: cross-cutting issues for eradication | Q33808738 | ||
| A Research Agenda to Underpin Malaria Eradication | Q33818020 | ||
| Aminoindoles, a novel scaffold with potent activity against Plasmodium falciparum | Q33851108 | ||
| Malaria gametocytogenesis | Q33894262 | ||
| Revisiting the circulation time of Plasmodium falciparum gametocytes: molecular detection methods to estimate the duration of gametocyte carriage and the effect of gametocytocidal drugs | Q33898575 | ||
| Pharmacological properties of a new antimalarial bisthiazolium salt, T3, and a corresponding prodrug, TE3. | Q33935408 | ||
| Structure-activity relationships of 4-position diamine quinoline methanols as intermittent preventative treatment (IPT) against Plasmodium falciparum | Q33997571 | ||
| Design and synthesis of small molecular dual inhibitor of falcipain-2 and dihydrofolate reductase as antimalarial agent | Q39672806 | ||
| Deciphering the Resistance-Counteracting Functions of Ferroquine in Plasmodium falciparum-Infected Erythrocytes | Q39734520 | ||
| New anti-malarial phenylpropanoid conjugated iridoids from Morinda morindoides. | Q39740789 | ||
| Synthesis and evaluation of phenylequine for antimalarial activity in vitro and in vivo | Q39759075 | ||
| Pharmacokinetics of piperaquine after repeated oral administration of the antimalarial combination CV8 in 12 healthy male subjects | Q40338733 | ||
| Malaria-infected mice are completely cured by one 6 mg/kg oral dose of a new monomeric trioxane sulfide combined with mefloquine | Q40369518 | ||
| Efficacy of oral single dose therapy with artemisinin-naphthoquine phosphate in uncomplicated falciparum malaria | Q40388919 | ||
| A class of potent antimalarials and their specific accumulation in infected erythrocytes | Q40750735 | ||
| Plasmodium falciparum gametocytes: their longevity and infectivity | Q40752602 | ||
| The action of metabolic inhibitors on microgametogenesis in Plasmodium yoelii nigeriensis | Q41776885 | ||
| Chloroquine increases Plasmodium falciparum gametocytogenesis in vitro. | Q41924042 | ||
| Vaccines: The take-home lesson | Q41929699 | ||
| A new class of phenazines with activity against a chloroquine resistant Plasmodium falciparum strain and antimicrobial activity | Q41932739 | ||
| New imidazolidinedione derivatives as antimalarial agents | Q41933757 | ||
| Bis-alkylamine quindolone derivatives as new antimalarial leads | Q41935132 | ||
| Synthesis, antimalarial activity, and preclinical pharmacology of a novel series of 4'-fluoro and 4'-chloro analogues of amodiaquine. Identification of a suitable "back-up" compound for N-tert-butyl isoquine. | Q41938916 | ||
| Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for the 21st century | Q41939096 | ||
| Novel inhibitor of Plasmodium histone deacetylase that cures P. berghei-infected mice | Q42098631 | ||
| New approach for high-throughput screening of drug activity on Plasmodium liver stages | Q42121275 | ||
| Transport and pharmacodynamics of albitiazolium, an antimalarial drug candidate | Q42324155 | ||
| Comparison and Optimization of Different Methods for the In Vitro Production of Plasmodium falciparum Gametocytes | Q42560487 | ||
| Disulfide prodrugs of albitiazolium (T3/SAR97276): synthesis and biological activities. | Q42718072 | ||
| Evaluation of bis-alkylamidoxime O-alkylsulfonates as orally available antimalarials. | Q42718584 | ||
| Synthesis and in vitro antiprotozoal activities of 5-phenyliminobenzo[a]phenoxazine derivatives | Q42727313 | ||
| Synthesis, structure-activity relationship, and antimalarial activity of ureas and thioureas of 15-membered azalides | Q42743441 | ||
| Potent antiprotozoal activity of a novel semi-synthetic berberine derivative. | Q42743627 | ||
| Synthesis and antimalarial assessment of a new series of orally active amino-functionalized spiro 1,2,4-trioxanes | Q42862617 | ||
| Endochin optimization: structure-activity and structure-property relationship studies of 3-substituted 2-methyl-4(1H)-quinolones with antimalarial activity | Q42912336 | ||
| Falcipain Inhibitors: Optimization Studies of the 2-Pyrimidinecarbonitrile Lead Series | Q42951472 | ||
| Exploration of potential prodrug approach of the bis-thiazolium salts T3 and T4 for orally delivered antimalarials. | Q42982619 | ||
| 6-(4'-Aryloxy-phenyl)vinyl-1,2,4-trioxanes: a new series of orally active peroxides effective against multidrug-resistant Plasmodium yoelii in Swiss mice | Q42991396 | ||
| Editorial commentary: single-dose primaquine as gametocytocidal treatment in patients with uncomplicated falciparum malaria | Q43149117 | ||
| The comparative antimalarial properties of weak base and neutral synthetic ozonides | Q43229262 | ||
| Synthesis and evaluation of hybrid bis-cationic salts as antimalarial drugs. | Q43234703 | ||
| Antiplasmodial activity of piperazine sulfonamides | Q43242186 | ||
| Effects of antimalarial molecules on the gametocyte stage of Plasmodium falciparum: the debate | Q43543088 | ||
| Control of malaria | Q44008732 | ||
| Perspectives: The missing pieces | Q44163652 | ||
| A high-throughput assay for the identification of malarial transmission-blocking drugs and vaccines | Q44166008 | ||
| Pyrimethamine-sulfadoxine resistance in Plasmodium falciparum must be delayed in Africa | Q44179422 | ||
| In vivo efficacy of mefloquine for the treatment of Falciparum malaria in Brazil | Q44597437 | ||
| Antiplasmodial agents from the Bhutanese medicinal plant Corydalis calliantha. | Q45983206 | ||
| Novel bis- and tris-1,2,4-trioxanes: synthesis and antimalarial activity against multidrug-resistant Plasmodium yoelii in Swiss mice | Q46249132 | ||
| Discovery of novel 1H-imidazol-2-yl-pyrimidine-4,6-diamines as potential antimalarials | Q47946828 | ||
| Determining the absolute configuration of (+)-mefloquine HCl, the side-effect-reducing enantiomer of the antimalaria drug Lariam | Q47996976 | ||
| Linker-based hemisuccinate derivatives of artemisinin: synthesis and antimalarial assessment against multidrug-resistant Plasmodium yoelii nigeriensis in mice | Q47998943 | ||
| The numbers game | Q48007998 | ||
| Drug development: Holding out for reinforcements | Q48008007 | ||
| A pharmacokinetic approach to assess artemisinin-naphthoquine combination therapy for uncomplicated pediatric malaria | Q48024466 | ||
| Intersex effect of lamotrigine on the pharmacokinetic parameters of CDRI-97/78, a novel trioxane antimalarial compound, in rats. | Q51346130 | ||
| Malaria | Q56767483 | ||
| Broadly applicable synthesis of 1,2,4,5-tetraoxanes | Q83100273 | ||
| Benzoxaborole antimalarial agents. Part 2: Discovery of fluoro-substituted 7-(2-carboxyethyl)-1,3-dihydro-1-hydroxy-2,1-benzoxaboroles | Q83239769 | ||
| CoMSIA and POM analyses of anti-malarial activity of synthetic prodiginines | Q84457169 | ||
| Artemisone effective against murine cerebral malaria | Q34084173 | ||
| Heat shock protein 90: inhibitors in clinical trials. | Q34091401 | ||
| Assessment of azithromycin in combination with other antimalarial drugs against Plasmodium falciparum in vitro | Q34111879 | ||
| Diversity-Oriented Synthesis Yields a Novel Lead for the Treatment of Malaria | Q34157359 | ||
| Efficacy and safety of artemisinin-naphthoquine versus dihydroartemisinin-piperaquine in adult patients with uncomplicated malaria: a multi-centre study in Indonesia | Q34254961 | ||
| Imidazolopiperazines: lead optimization of the second-generation antimalarial agents | Q34270117 | ||
| Selective and specific inhibition of the plasmodium falciparum lysyl-tRNA synthetase by the fungal secondary metabolite cladosporin | Q34306714 | ||
| The global public health significance of Plasmodium vivax. | Q34314657 | ||
| Small-molecule histone methyltransferase inhibitors display rapid antimalarial activity against all blood stage forms in Plasmodium falciparum | Q34421556 | ||
| A class of tricyclic compounds blocking malaria parasite oocyst development and transmission | Q34467923 | ||
| Pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: what next? | Q34470236 | ||
| Whole-cell in vitro screening for gametocytocidal compounds | Q34509609 | ||
| Targeting the ERAD pathway via inhibition of signal peptide peptidase for antiparasitic therapeutic design | Q34510075 | ||
| Vector control: The last bite | Q34637816 | ||
| A chemotype that inhibits three unrelated pathogenic targets: the botulinum neurotoxin serotype A light chain, P. falciparum malaria, and the Ebola filovirus. | Q34665879 | ||
| Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria | Q34693880 | ||
| The structure-activity relationship of the antimalarial ozonide arterolane (OZ277). | Q35013670 | ||
| In vivo and in vitro antimalarial properties of azithromycin-chloroquine combinations that include the resistance reversal agent amlodipine | Q35065754 | ||
| Lead optimization of aryl and aralkyl amine-based triazolopyrimidine inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with antimalarial activity in mice | Q35071496 | ||
| Antimalarial activity of the bisquinoline trans-N1,N2-bis (7-chloroquinolin-4-yl)cyclohexane-1,2-diamine: comparison of two stereoisomers and detailed evaluation of the S,S enantiomer, Ro 47-7737 | Q35134156 | ||
| Radical curative efficacy of tafenoquine combination regimens in Plasmodium cynomolgi-infected Rhesus monkeys (Macaca mulatta) | Q35181605 | ||
| Discovery of novel alkylated (bis)urea and (bis)thiourea polyamine analogues with potent antimalarial activities | Q35318393 | ||
| Lead optimization of antimalarial propafenone analogues. | Q35535315 | ||
| A chemical genomic analysis of decoquinate, a Plasmodium falciparum cytochrome b inhibitor | Q35563452 | ||
| Quantitative assessment of Plasmodium falciparum sexual development reveals potent transmission-blocking activity by methylene blue | Q35571456 | ||
| Cyclopropyl carboxamides, a chemically novel class of antimalarial agents identified in a phenotypic screen | Q35598598 | ||
| Cytotoxic effect of curcumin on malaria parasite Plasmodium falciparum: inhibition of histone acetylation and generation of reactive oxygen species | Q35635984 | ||
| Adherence to a six-dose regimen of artemether-lumefantrine among uncomplicated Plasmodium falciparum patients in the Tigray Region, Ethiopia | Q35642797 | ||
| Febrifugine analogue compounds: synthesis and antimalarial evaluation | Q35675211 | ||
| Identification, design and biological evaluation of bisaryl quinolones targeting Plasmodium falciparum type II NADH:quinone oxidoreductase (PfNDH2). | Q35814421 | ||
| Artemisinin-naphthoquine combination therapy for uncomplicated pediatric malaria: a pharmacokinetic study | Q35941440 | ||
| Artemisinin-naphthoquine combination therapy for uncomplicated pediatric malaria: a tolerability, safety, and preliminary efficacy study | Q35941455 | ||
| Lead optimization of 3-carboxyl-4(1H)-quinolones to deliver orally bioavailable antimalarials | Q35951799 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | drug discovery | Q1418791 |
| malaria | Q12156 | ||
| P304 | page(s) | 2829-43 | |
| P577 | publication date | 2013-05-15 | |
| P1433 | published in | Bioorganic & Medicinal Chemistry Letters | Q2709483 |
| P1476 | title | Recent advances in malaria drug discovery | |
| P478 | volume | 23 |
| Q42707908 | 7-chloroquinoline-isatin conjugates: antimalarial, antitubercular, and cytotoxic evaluation |
| Q57835915 | A critical evaluation of pyrrolo[2,3-d]pyrimidine-4-amines as Plasmodium falciparum apical membrane antigen 1 (AMA1) inhibitors |
| Q28070398 | Alternatives to currently used antimalarial drugs: in search of a magic bullet |
| Q26768112 | Anti-parasitic Peptides from Arthropods and their Application in Drug Therapy |
| Q47784982 | Antischistosomal agents: state of art and perspectives |
| Q39008583 | Biologically active carbazole derivatives: focus on oxazinocarbazoles and related compounds. |
| Q35093829 | Computational Study on the Effect of Exocyclic Substituents on the Ionization Potential of Primaquine: Insights into the Design of Primaquine-Based Antimalarial Drugs with Less Methemoglobin Generation |
| Q47964175 | Crystal structure of truncated aspartate transcarbamoylase from Plasmodium falciparum. |
| Q52708722 | Design, synthesis and biological evaluation of new carbazole derivatives as anti-cancer and anti-migratory agents. |
| Q91704431 | Design, synthesis, heme binding and density functional theory studies of isoindoline-dione-4-aminoquinolines as potential antiplasmodials |
| Q53696257 | Differential activity of methylene blue against erythrocytic and hepatic stages of Plasmodium. |
| Q38915797 | Discovery and Characterization of ACT-451840: an Antimalarial Drug with a Novel Mechanism of Action |
| Q28365208 | Domestic trends in malaria research and development in China and its global influence |
| Q56794569 | Effects of Amino Acid Deletion on the Antiplasmodial Activity of Angiotensin II |
| Q48013081 | Efficient Synthesis of 1,9-Substituted Benzo[h][1,6]naphthyridin-2(1H)-ones and Evaluation of their Plasmodium falciparum Gametocytocidal Activities |
| Q52342771 | Encapsulation of OZ439 into Nanoparticles for Supersaturated Drug Release in Oral Malaria Therapy. |
| Q60935384 | Evaluating antimalarial efficacy by tracking glycolysis in Plasmodium falciparum using NMR spectroscopy |
| Q91628212 | Evaluation of Antimalarial Activity of the 80% Methanolic Stem Bark Extract of Combretum molle Against Plasmodium berghei in Mice |
| Q33636531 | Evaluation of aminohydantoins as a novel class of antimalarial agents. |
| Q38668340 | Everybody needs sphingolipids, right! Mining for new drug targets in protozoan sphingolipid biosynthesis |
| Q37334397 | Exploring the scope of new arylamino alcohol derivatives: Synthesis, antimalarial evaluation, toxicological studies, and target exploration |
| Q37348404 | Fast in vitro methods to determine the speed of action and the stage-specificity of anti-malarials in Plasmodium falciparum |
| Q36026159 | Functionalized Benzimidazole Scaffolds: Privileged Heterocycle for Drug Design in Therapeutic Medicine. |
| Q39534582 | Hologram QSAR studies of antiprotozoal activities of sesquiterpene lactones. |
| Q36912176 | Identification of New Human Malaria Parasite Plasmodium falciparum Dihydroorotate Dehydrogenase Inhibitors by Pharmacophore and Structure-Based Virtual Screening |
| Q91657902 | Lerisetron Analogues with Antimalarial Properties: Synthesis, Structure-Activity Relationship Studies, and Biological Assessment |
| Q38497838 | Malaria medicines: a glass half full? |
| Q34142744 | Metabolomics in the fight against malaria. |
| Q35889482 | Natural product-based synthesis of novel anti-infective isothiocyanate- and isoselenocyanate-functionalized amphilectane diterpenes |
| Q35671066 | Network-based gene prediction for Plasmodium falciparum malaria towards genetics-based drug discovery |
| Q38260909 | New insight-guided approaches to detect, cure, prevent and eliminate malaria |
| Q47551575 | Novel Immunoinformatics Approaches to Design Multi-epitope Subunit Vaccine for Malaria by Investigating Anopheles Salivary Protein |
| Q48020714 | Optimization of Physicochemical Properties for 4-Anilinoquinoline Inhibitors of Plasmodium falciparum Proliferation |
| Q59391603 | Optimized Synthesis and Antimalarial Activity of 1,2-Dioxane-4-carboxamides |
| Q57790745 | Orally Effective Aminoalkyl 10H-Indolo-[3,2-b]quinoline-11-carboxamide Kills the Malaria Parasite by Inhibiting Host Hemoglobin Uptake |
| Q35892823 | Original 2-(3-Alkoxy-1H-pyrazol-1-yl)azines Inhibitors of Human Dihydroorotate Dehydrogenase (DHODH) |
| Q92938992 | Phthalimide Derivatives with Bioactivity against Plasmodium falciparum: Synthesis, Evaluation, and Computational Studies Involving bc 1 Cytochrome Inhibition |
| Q41913089 | Piperazine-linked 4-aminoquinoline-chalcone/ferrocenyl-chalcone conjugates: Synthesis and antiplasmodial evaluation |
| Q40331757 | Polyamidoamine nanoparticles as nanocarriers for the drug delivery to malaria parasite stages in the mosquito vector |
| Q43241737 | PrEP Implementation Science: State-of-the-Art and Research Agenda |
| Q90107130 | Quantitative structure-activity relationship to predict the anti-malarial activity in a set of new imidazolopiperazines based on artificial neural networks |
| Q47852744 | Realistically, how far are we from a universal malaria drug? |
| Q26799360 | Recent Developments and Biological Activities of N-Substituted Carbazole Derivatives: A Review |
| Q28069435 | Recent advances in malaria genomics and epigenomics |
| Q27976471 | Small molecule screen for candidate antimalarials targeting Plasmodium Kinesin-5 |
| Q64062567 | Spray drying OZ439 nanoparticles to form stable, water-dispersible powders for oral malaria therapy |
| Q41917145 | Synthesis and Antiplasmodial Activity of Novel Chloroquine Analogues with Bulky Basic Side Chains |
| Q49730843 | Synthesis and antiplasmodial activity of novel phenanthroline derivatives: An in vivo study. |
| Q38682904 | Synthesis and in vivo antimalarial activity of novel naphthoquine derivatives with linear/cyclic structured pendants |
| Q92178094 | Synthesis, Anti-Cancer and Anti-Migratory Evaluation of 3,6-Dibromocarbazole and 5-Bromoindole Derivatives |
| Q35875723 | The promises and challenges of pre-exposure prophylaxis as part of the emerging paradigm of combination HIV prevention |
| Q41588963 | Virtual-screening workflow tutorials and prospective results from the Teach-Discover-Treat competition 2014 against malaria |
Search more.